Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Laparoscopic splenectomy's effect on liver function in cirrhosis patients

Official title: The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients

Run by Northern Jiangsu People's Hospital · NCT05325424 · Data updated 2026-11-12

This study tests if a minimally invasive surgery to remove the spleen can improve liver function in patients with cirrhosis.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorNorthern Jiangsu People's Hospital
Academic / other
Locations1 site (Yangzhou, Jiangsu)
StatusRecruiting
StartedMarch 1, 2022
Main results expectedJuly 31, 2025
Study endsJuly 31, 2025
Registry record updatedMay 30, 2025
Trial IDNCT05325424 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with cirrhosis and splenomegaly who have a platelet count below 50*10^9/L.

Probably not a fit

Patients with advanced liver disease (Child-Pugh grade C), malignancies, or other serious health conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of laparoscopic splenectomy on liver reserve function in patients diagnosed with cirrhosis. Participants undergo the surgical procedure, and their liver function indicators are monitored at multiple time points post-surgery. The goal is to determine if this surgical intervention can enhance liver function and improve overall patient prognosis. A standardized treatment and follow-up plan is implemented to ensure consistency in patient care.

Why it matters

Potential benefit: If successful, this approach could significantly improve liver function and quality of life for patients with cirrhosis.

How similar studies have gone: While similar studies have explored the effects of splenectomy on liver function, this specific approach and its outcomes in cirrhosis patients are relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
* Splenomegaly with secondary hypersplenism, Platelet count \< 50\*10\^9/L
* Informed consent to participate in the study

Exclusion Criteria:

* Hepatocellular carcinoma or any other malignancy,
* Child-Pugh grade C
* Recent peptic ulcer disease
* History of Hemorrhagic stroke
* Pregnancy.
* Uncontrolled Hypertension
* Bleeding portal hypertension
* Human immunodeficiency virus (HIV) infection

Where it's running

  • Clinical Medical College of Yangzhou University
    Yangzhou, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.